What is Claimed:

~~1. A compound of Formula (II):~~



(II)

~~or a pharmaceutically acceptable salt thereof, wherein:~~

~~R^3 is F or OH;~~

~~R^4 is CN or halomethyl;~~

~~R^6 is OH; and~~

~~R^5 is selected from the group of H and:~~



,

,

,



and



;

wherein:

n' is selected from 1, 2, 3, and 4;

R^8 is selected from C_1-C_8 alkyl, -O-C_1-C_8 alkyl, benzyl, -O-benzyl, $-CH_2$-C_3-C_6 cycloalkyl, -O-CH_2-C_3-C_6 cycloalkyl, and CF_3;

R^9 is selected from phenyl, 1-naphthyl, 2-naphthyl,



;

R^{10} is selected from H and CH_3;

R^{11} is selected from H and C_1-C_6 alkyl; and

R^{12} is selected from H, C_1-C_8 alkyl, benzyl, C_3-C_6 cycloalkyl, and $-CH_2$-C_3-C_6 cycloalkyl.

2. The compound or the pharmaceutically acceptable salt of claim 1, wherein R^9 is phenyl.

3. The compound or the pharmaceutically acceptable salt of claim 1 or 2, wherein R^3 is OH.

4. The compound or the pharmaceutically acceptable salt of any one of claims 1-3, wherein:

(i) R^4 is CN, $-CH_2Cl$, $-CH_2F$, $-CHF_2$, or $-CF_3$; or

(ii) R^4 is CN.

5. A compound or the pharmaceutically acceptable salt of any one of claims 1-4, wherein:

(i) R^5 is H; or

(ii) R^5 is selected from the group of:





, and



; ~~wherein~~

~~R^8 is selected from C_1-C_8 alkyl, -O-C_1-C_8 alkyl, benzyl, and -CH_2-C_3-C_6 cycloalkyl; and~~

~~R^{12} is selected from C_1-C_8 alkyl, benzyl, C_3-C_6 cycloalkyl, and -CH_2-C_3-C_6 cycloalkyl.~~

~~6. The compound or the pharmaceutically acceptable salt of claim 5, wherein R^5 is~~



~~or~~



.

~~7. The compound or the pharmaceutically acceptable salt of claim 1, wherein the compound is:~~



.

~~8. The compound or the pharmaceutically acceptable salt of claim 1, wherein the compound is:~~



~~9. The compound or the pharmaceutically acceptable salt of claim 1, wherein the compound is:~~



~~10. The compound or the pharmaceutically acceptable salt of claim 1, wherein the compound is selected from the group consisting of:~~





~~, and~~



~~11. The compound or the pharmaceutically acceptable salt of claim 1, wherein R^3 is F, R^4 is CN; R^5 is~~



;

~~or~~



~~; and R^9 is phenyl.~~

~~12. The compound or the pharmaceutically acceptable salt of claim 11, wherein R^5 is~~



or



;

~~wherein~~

~~R^8 is selected from C_1-C_8 alkyl, -O-C_1-C_8 alkyl, benzyl, and -CH_2-C_3-C_6 cycloalkyl; and~~

~~R^{12} selected from H, C_1-C_8 alkyl, benzyl, C_3-C_6 cycloalkyl, and -CH_2-C_3-C_6 cycloalkyl.~~

~~13. The compound or the pharmaceutically acceptable salt of claims 11 or 12, wherein R^8 is C_1-C_8 alkyl, C_1-C_6 alkyl, or C_1-C_4 alkyl.~~

~~14. Use of the compound or the pharmaceutically acceptable salt of any one of claims 1-13 in treating a *Pneumovirinae* virus infection in a human in need thereof.~~

~~15. A pharmaceutical formulation comprising a pharmaceutically effective amount of the compound or the pharmaceutically acceptable salt of any one of claims 1-12 and a pharmaceutically acceptable carrier or excipient.~~

1. A compound of Formula (II):



(II)

or a pharmaceutically acceptable salt thereof, wherein:

R^3 is OH or F;

R^4 is CN or halomethyl;

R^6 is OH; and

R^5 is selected from the group of H and:





and



;

wherein:

n' is selected from 1, 2, 3, and 4;

R^8 is selected from C_1-C_8 alkyl, -O-C_1-C_8 alkyl, benzyl, -O-benzyl, -CH_2-C_3-C_6 cycloalkyl, -O-CH_2-C_3-C_6 cycloalkyl, and CF_3;

R^9 is selected from phenyl, 1-naphthyl, 2-naphthyl,



, and 

;

R^{10} is selected from H and CH_3;

R^{11} is selected from H and C_1-C_6 alkyl; and

R^{12} is selected from H, C_1-C_8 alkyl, benzyl, C_3-C_6 cycloalkyl, and $–CH_2$-C_3-C_6 cycloalkyl.

2. The compound or pharmaceutically acceptable salt of claim 1, wherein R^9 is phenyl.

3. The compound or the pharmaceutically acceptable salt of claim 1 or 2, wherein R^3 is OH.

4. The compound or the pharmaceutically acceptable salt of any one of claims 1-3, wherein R^4 is CN, $-CH_2Cl$, $-CH_2F$, $-CHF_2$, or $–CF_3$.

5. The compound or the pharmaceutically acceptable salt of any one of claims 1-3, wherein R^4 is CN.

6. The compound or the pharmaceutically acceptable salt of any one of claims 1-5 wherein R^5 is H.

7. The compound or the pharmaceutically acceptable salt of any one of claims 1-5 wherein R^5 is selected from the group of:



, 

, 

,



wherein:

R^8 is selected from C_1-C_8 alkyl, -O-C_1-C_8 alkyl, benzyl, and -CH_2-C_3-C_6 cycloalkyl; and R^{12} is selected from C_1-C_8 alkyl, benzyl, C_3-C_6 cycloalkyl, and –CH_2-C_3-C_6 cycloalkyl.

8. The compound or the pharmaceutically acceptable salt of claim 7, wherein R^5 is



9. The compound or the pharmaceutically acceptable salt of claim 1, wherein the compound is:



10. The compound or the pharmaceutically acceptable salt of claim 1, wherein the compound is:



.

11. The compound or the pharmaceutically acceptable salt of claim 1, wherein the compound is:



.

12. The compound or the pharmaceutically acceptable salt of claim 1, wherein the compound is selected from the group consisting of:



,



, and



.

13. The compound or the pharmaceutically acceptable salt of claim 1, wherein R^3 is F, R^4 is CN; R^5 is



; or  ; and R^9 is phenyl.

14. The compound or the pharmaceutically acceptable salt of claim 13, wherein R^5 is

 or  ;

wherein

R^8 is selected from C_1-C_8 alkyl, -O-C_1-C_8 alkyl, benzyl, and -CH_2-C_3-C_6 cycloalkyl; and

R^{12} selected from H, C_1-C_8 alkyl, benzyl, C_3-C_6 cycloalkyl, and –CH_2-C_3-C_6 cycloalkyl.

15. The compound or the pharmaceutically acceptable salt of claim 13 or 14, wherein R^8 is C_1-C_8 alkyl, C_1-C_6 alkyl or C_1-C_4 alkyl.

16. Use of the compound or the pharmaceutically acceptable salt of any one of claims 1-15 in the manufacture of a medicament for the treatment of a *Pneumovirinae* virus infection in a human in need thereof.

17. A pharmaceutical formulation comprising a pharmaceutically effective amount of the compound or the pharmaceutically acceptable salt of any one of claims 1-15 and a pharmaceutically acceptable carrier or excipient.